Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by Oilminerdeluxeon Jan 25, 2021 5:38am
195 Views
Post# 32373215

RE:Revenues

RE:Revenues

Covid tests are the only real income of worth. ColonSentry can however be used in other ways. Like being shoved up the bashers' a...

If revenue is the same this Q, or slightly higher, I will be happy. I supect costs will have increased a lot as they prepare for the launch of Aristotle, staff hirings etc etc.  I have developed a fear whenever JHT speaks of sales and revenue, so I do not expect too much when they tell us next time how things are going. I bet most will be angry when next Q is reported. However, that is of less importance right now imho, since Aristotle will be on everyone's mind. I hope they have built a strong network to make it a success and not be a clone of previous outcomes. We will see, this is what long suffering shareholders have been waiting for, so exciting times. I will be happy for them if success arrives.

<< Previous
Bullboard Posts
Next >>